0000000001210872

AUTHOR

Evelina Mockiene

showing 1 related works from this author

Direct-acting antivirals ombitasvir/paritaprevir/rotonavir+dasabuvir with or without ribavirin in hepatitis C virus (HCV) genotype 1-infected treatme…

2018

Background: The current international multicentre open-label, uncontrolled, real-world retrospective study aimed at evaluating the effectiveness and safety of ombitasvir / paritaprevir / ritonavir + dasabuvir ± ribavirin (3D therapy) in treatment-naive and treatment-experienced hepatitis C virus (HCV) genotype 1-infected (GT1) patients. Methods: Adult patients with chronic HCV GT1 infection, scheduled for 3D therapy according to therapeutic guidelines, were eligible. Demographic and clinical data were collected retrospectively by reviewing individuals health records. The primary effectiveness endpoint was the sustained virological response at 12 weeks following the end of treatment (SVR12).…

medicine.medical_specialtyDasabuvirCirrhosisHepatologymedicine.diagnostic_testbusiness.industryRibavirinmedicine.diseaseOmbitasvir03 medical and health scienceschemistry.chemical_compoundRegimen0302 clinical medicineInfectious DiseaseschemistryParitaprevirInternal medicinemedicine030211 gastroenterology & hepatologyRitonavir030212 general & internal medicineChronic hepatitis C ; genotype-1HCV ; ombitasvir ; paritaprevir ; dasabuvir ; cirrhosis ; liver transplant ; 3D therapyLiver function testsbusinessmedicine.drug
researchProduct